ArriVent BioPharma Inc
For the period ended Dec 31, 2024. Filed Mar 3, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 3, 2025
AVBP$13.49-4.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2024 and 2023
BALANCE SHEETS
| | | | | | | |
|---|---|---|---|---|---|---|
| · · December 31, | ||||||
| · 2024 · 2023 | ||||||
| Assets · · | ||||||
| Current assets: · · | ||||||
| Cash and cash equivalents | | $74,293 | | $150,389 | ||
| Short-term investments | | | 144,570 | | | — |
| Prepaid expenses and other current assets | | 8,116 | | 9,579 | ||
| Total current assets | | 226,979 | | 159,968 | ||
| Long-term investments | | | 47,683 | | | — |
| Right of use assets – operating leases | | 154 | | 291 | ||
| Deferred offering costs | | | — | | | 2,732 |
| Other assets | | 126 | | 107 | ||
| Total assets | | $274,942 | | $163,098 | ||
| | | | | | | |
| Liabilities, Convertible Preferred Stock and Stockholders’ Equity (Deficit) | | | ||||
| Current liabilities: | | | ||||
| Accounts payable | | $3,782 | | $4,532 | ||
| Accrued expenses | | 13,330 | | 6,952 | ||
| Operating lease liabilities | | 162 | | 140 | ||
| Total current liabilities | | 17,274 | | 11,624 | ||
| Operating lease liabilities, net of current amount | | 14 | | 177 | ||
| Total liabilities | | 17,288 | | 11,801 | ||
| | | | | | | |
| Commitments and contingencies (Note 7) | | | ||||
| | | | | | | |
| Series A convertible preferred stock $0.0001 par value, 150,000,000 shares authorized; 0 and 150,000,000 shares issued and outstanding at December 31, 2024 and 2023, respectively | | — | | 149,865 | ||
| Series B convertible preferred stock $0.0001 par value, 147,619,034 shares authorized; 0 and 147,619,034 shares issued and outstanding at December 31, 2024 and 2023, respectively | | | — | | | 154,625 |
| | | | | | | |
| Stockholders’ equity (deficit): | | | | | | |
| Preferred stock $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding | | — | | — | ||
| Common stock $0.0001 par value, 200,000,000 shares authorized; 33,706,765 and 2,745,480 shares issued and outstanding at December 31, 2024 and 2023, respectively | | | 3 | | | — |
| Additional paid-in capital | | 496,195 | | 4,652 | ||
| Accumulated deficit | | (238,333) | | (157,845) | ||
| Accumulated other comprehensive (loss) | | | (211) | | | — |
| Total stockholders’ equity (deficit) | | 257,654 | | (153,193) | ||
| Total liabilities, convertible preferred stock and stockholders’ equity (deficit) | | $274,942 | | $163,098 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.